Market Trends of Thalassemia Treatment Industry
This section covers the major market trends shaping the Thalassemia Treatment Market according to our research experts:
Chelation Therapy segment is expected to be the Fastest Growing Segment
- Iron overload is the main cause of sickness for thalassemia patients. Even non- transfused patients develop iron overload secondary to boosted intestinal absorption of dietary iron. Iron overload is a leading cause of mortality and organ injury. The only treatment options for removing excess iron are phlebotomy and chelation. While phlebotomy is a very effective way of removing iron, it is not appropriate for patients with thalassemia except after bone marrow transplantation.
- The segment is projected to expand at an exponential growth rate during the forecast period. The major factors driving the growth of the segment are increasing incidence of thalassemia patients and increasing research and development investments.
North America Dominates the Market and Expected to do Same in the Forecast Period
North America is expected to dominate the overall thalassemia treatment market, throughout the forecast period. The market growth is due to the factors such as the presence of key players, high prevalence of thalassemia patients in the region and established healthcare infrastructure are some of the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and increase in number of research partnerships are some of the drivers expected to increase the market growth. The United States has the main share due to the rising awareness about the condition and increasing number of populations with thalassemia carrier gene, and growth in birth rates due to variation of genes among the population.
